Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gemcitabine for Marginal Zone Lymphoma

This study has been terminated.
(poor accrual and response less than expected on interim analysis)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00337259
First received: June 14, 2006
Last updated: May 4, 2009
Last verified: May 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)